Cambridge Healthtech Institute’s 8th Annual

Rapid Methods to Assess Quality & Stability of Biologics

Accelerating Prediction and Screening

August 24-25, 2020

 

The eighth annual Rapid Methods to Assess Quality & Stability of Biologics conference will bring together experts in analytical and formulation development to discuss rapid and practical ways to accelerate prediction and screening for protein stability and instabilities in early- and late-stage development. We are seeking case studies, unpublished work on new methods and tools employed in real-time and accelerated stability studies for proteins, cell and gene therapy products, high-throughput analytics, developability assessment, multi-attribute methods, biophysical methods, HOS, use of DOE and QbD, and immunogenicity.

Preliminary Agenda

RAPID DEVELOPABILITY AND STABILITY ASSESSMENT

An Industry Perspective on Forced Degradation Studies of Biopharmaceuticals: Survey Outcome and Recommendations

Christoph Grapentin, PhD, Associate Principal Scientist, Formulation Development, Lonza and BioPhorum Development Group

Assessment of Instrumentational Factors in Dynamic Light Scattering (DLS) on Nanomedicine Size Characterization

Lin Jin, PhD, Scientist, Analytical Development, Moderna, Inc.

Developing Analytical Techniques for Rapid Structure and Stability Assessment of Protein Therapeutics

Michael B. Goshe, PhD, Associate Professor of Biochemistry, Molecular and Structural Biochemistry, North Carolina State University

Biologics Formulation Development

Ashlesha S. Raut, Associate Principal Scientist, Sterile Formulation Sciences, Merck & Co., Inc.

HIGH-THROUGHPUT FORMULATION SCREENING

Evaluation of Crystal Zenith Microtiter Plates for High-Throughput Formulation Screening

Alaina Floyd, PhD, Senior Scientist, Drug Product Design, Just - Evotec Biologics, Inc.

High-Throughput Biophysical Characterization to Measure Therapeutic Protein Developability in Early Discovery

Andrew K. Urick, PhD, Senior Scientist, Biologics Generation Group, AbbVie Bioresearch Center

PROTEIN-PROTEIN INTERACTIONS, PROTEIN AGGREGATES AND IMMUNOGENICITY

Ambient Light and UV Emission: Effect of Protein Concentration and Surface Exposed Tryptophan on Monoclonal Antibody Aggregation

Haresh T. More, PhD, Research Investigator II, Parenteral Science and Technology, Bristol-Myers Squibb

Optimizing Protein-Surfactant Bulk and Interfacial Interactions through Advanced Characterization Techniques for Controlling Aggregation and Viscosity

Samiul Amin, PhD, Associate Professor, Chemical Engineering, Manhattan College

Mechanism for the Screening of Patchy Anisotropic Interactions in Protein Solutions Using Hydrophobic Excipients

Speaker to be Announced




For more details on the conference, please contact:
Nandini Kashyap, MPharm
Conference Director
Cambridge Healthtech Institute

Phone: (+1) 781-972-5406
Email: nkashyap@healthtech.com

 

For partnering and sponsorship information, please contact:

Companies A-K
Sherry Johnson
Senior Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-1359
Email: sjohnson@healthtech.com

Companies L-Z
Carolyn Cooke
Manager, Business Development
Cambridge Healthtech Institute
Phone: (+1) 781-972-5412
Email: ccooke@healthtech.com



Premier Sponsors:

Fujifilm-Diosynth-Logo

NanotemperTechnologies

Samsung_Biologics

UnchainedLabs
Vironova